Article thumbnail

The causes, consequences, and treatment of left or right heart failure

By Pablo Pazos-López, Jesús Peteiro-Vázquez, Ana Carcía-Campos, Lourdes García-Bueno, Juan Pablo Abugattas de Torres and Alfonso Castro-Beiras

Abstract

Chronic heart failure (HF) is a cardiovascular disease of cardinal importance because of several factors: a) an increasing occurrence due to the aging of the population, primary and secondary prevention of cardiovascular events, and modern advances in therapy, b) a bad prognosis: around 65% of patients are dead within 5 years of diagnosis, c) a high economic cost: HF accounts for 1% to 2% of total health care expenditure. This review focuses on the main causes, consequences in terms of morbidity, mortality and costs and treatment of HF

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3096504
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A comparison of enalapril with hydralazine-isosorbidedinitrate in the treatment of chronic heart failure.
  2. A specific B2–bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril.
  3. Abnormal left ventricular filling: an early finding in mild to moderate systemic hypertension.
  4. ACE inhibition and hospitalisation rates for heart failure in the Netherlands 1980–1999. The end of an epidemic?
  5. Advanced heart failure treated with continuous-flow left ventricular assist device.
  6. (1996). Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail.
  7. (1987). Alterations in the coronary circulation in hypertrophied ventricles. Circulation.
  8. (1998). Angiotensin II receptor antagonists for heart failure.
  9. Angiotensin II receptor antagonists.
  10. Arrhythmogenic right ventricular cardiomyopathy.
  11. (2001). Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med.
  12. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis.
  13. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review.
  14. Cardiac- resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
  15. Cardiac-resynchronization therapy for the prevention of heart-failure events.
  16. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes.
  17. (2003). Cardiomyocyte apoptosis in hypertensive cardiomyopathy. Cardiovasc Res.
  18. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARMPreserved Trial.
  19. (1999). Chronic AT1 receptor blockade and angiotensin-converting enzyme (ACE) inhibition in (CHF 146) cardiomyopathic hamsters: effects on cardiac hypertrophy and survival. Cardiovasc Res.
  20. (1998). Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation.
  21. Chronic heart failure: contemporary diagnosis and management. Mayo Clin
  22. (2008). Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J.
  23. Clinical and functional determinants of coronary flow reserve in non-ischemic dilated cardiomyopathy: an echocardiographic study.
  24. Clinical and genetic issues in familial dilated cardiomyopathy.
  25. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry.
  26. Clinical epidemiology of heart failure.
  27. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure.
  28. (1998). Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. The NETWORK Investigators. Eur Heart J.
  29. clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy.
  30. (2004). Coats AJ; ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). Br Med J.
  31. Colucci WS. Digoxin in the management of cardiovascular disorders.
  32. Combination of isosorbidedinitrate and hydralazine in blacks with heart failure.
  33. (1994). Comparative pharmacokinetics and pharmacodynamics of loop diuretics in renal failure. Cardiology.
  34. (1991). Congestive heart failure in the community: a study of all incident cases in Olmsted County,
  35. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function.
  36. (2001). Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J.
  37. (2005). Coronary atherosclerosis in end stage idiopathic dilated cardiomyopathy: an innocent bystander? Eur Heart J.
  38. (1999). Coronary flow reserve of nonischemic heart failure. Congest Heart Fail.
  39. (1992). Cough and angioneuroticedema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med.
  40. (2002). CW; ADHERE Scientific Advisory Committee and Investigators. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations,
  41. Digoxin: a neurohormonal modulator in heart failure?
  42. (1996). Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet.
  43. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion.
  44. Echocardiographic evaluation of cardiac structure and function in elderly subjects with isolated systolic hypertension.
  45. Economic significance of heart failure. An overview of costs and economics of therapy.
  46. Effect of carvedilol on survival in severe chronic heart failure.
  47. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival
  48. Effect of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial.
  49. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).
  50. (1986). Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of the Veterans Administration Cooperative Study.
  51. Effects of controlledrelease metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF).
  52. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial.
  53. (2011). Eplerenone in patients with systolic heart failure and mild symptoms.
  54. (2003). Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
  55. (2008). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure
  56. (2010). Evidence-based management of right heart failure: a systematic review of an empiric field. Rev Esp Cardiol.
  57. Exercise performance following cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay.
  58. (2010). Exercise training for heart failure patients with and without systolic dysfunction: an evidence-based analysis of how patients benefit. Cardiol Res Pract.
  59. Feasibility and effectiveness of a disease and care management model in the primary health care system for patients with heart failure and diabetes (Project Leonardo). Vasc Health Risk Manag.
  60. (2009). Focused update incorporated into the ACC/AHA
  61. (2010). Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the
  62. for the ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure.
  63. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure.
  64. (1999). Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J.
  65. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
  66. Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure.
  67. Hibernating myocardium.
  68. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese.
  69. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry.
  70. (1985). Hospitalization of patients with heart failure: National Hospital Discharge Survey,
  71. (2000). Hypertensive heart disease. A complex syndrome or a hypertensive ‘cardiomyopathy’? Eur Heart J.
  72. I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction.
  73. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
  74. Interaction between nonsteroidal anti-inflammatory drugs and loop diuretics: modulation by sodium balance.
  75. Investigators. Coronary bypass surgery with or without surgical ventricular reconstruction.
  76. (2007). Isolated noncompaction of the left ventricular myocardium – a review of the literature two decades after the initial case description. Clin Res Cardiol.
  77. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure.
  78. (1989). Left ventricular diastolic dysfunction: early diastolic relaxation and late diastolic compliance.
  79. (2000). Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation.
  80. (2002). Long-term trends in the incidence of and survival with heart failure.
  81. Long-term use of a left ventricular assist device for end-stage heart failure.
  82. (2005). Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high risk acute myocardial infarction. Ann Intern Med. 2004;141(9):693–704. Erratum in: Ann Intern Med.
  83. Mitral valve surgery in advanced heart failure.
  84. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
  85. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis.
  86. (2010). Natriuretic peptide-guided management of patients with heart failure: a decade of progress but still a controversy. Future Cardiol.
  87. Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. Vasc Health Risk Manag.
  88. (2005). Natural history and familial characteristics of isolated left ventricular non-compaction.
  89. (2002). One-year mortality among unselected outpatients with heart failure. Eur Heart J.
  90. (2006). Origin of symptoms in chronic heart failure.
  91. (2006). Outcome of heart failure with preserved ejection fraction in a population-based study.
  92. (1995). Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure.
  93. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology.
  94. (1995). pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther.
  95. Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles.
  96. (2003). Prognosis for patients newly admitted to hospital with heart failure: survival trends
  97. (2004). Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J.
  98. (1990). Racial or ethnic differences in hospitalization for heart failure among elderly adults: Medicare,
  99. Randomized double-blind trial of darbepoetinalfa in patients with symptomatic heart failure and anemia.
  100. Randomized Spironolactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure.
  101. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms.
  102. (2005). Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J.
  103. Rapid ventricular filling in left ventricular hypertrophy: II. Pathologic hypertrophy.
  104. (2009). Relationship between blood pressure levels and adherence to medication in patients with chronic heart failure: how come? Vasc Health Risk Manag.
  105. (2004). Repair of ischemic mitral regurgitation does not increase mortality or improve long-term survival in patients undergoing coronary artery revascularization: a propensity analysis. Ann Thorac Surg.
  106. (2001). Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med.
  107. Six minute walk test: a simple and useful test to evaluate functional capacity in patients with heart failure.
  108. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.
  109. (1994). Structural remodelling in hypertensive heart disease and the roles of hormones. Hypertension.
  110. (2010). Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Cochrane Database Syst Rev.
  111. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardio-defibrillator for congestive heart failure.
  112. (2000). Survival of patients with a new diagnosis of heart failure: a population based study.
  113. (1996). Tachycardiomyopathy: mechanisms and clinical implications. Pacing Clin Electrophysiol.
  114. Telemedical Interventional Monitoring in Heart Failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure: study design.
  115. Telemonitoring in patients with heart failure.
  116. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
  117. The current cost of heart failure to the National Health Service in the UK.
  118. The effect of cardiac resynchronization on morbidity and mortality in heart failure.
  119. The effect of digoxin on mortality and morbidity in patients with heart failure.
  120. The effects of angiotensin-receptor blockers on mortality and morbidity in heart failure: a systematic review.
  121. The key to unraveling the mystery of mortality in heart failure: an integrated approach.
  122. (1996). The progression from hypertension to congestive heart failure.
  123. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial.
  124. (1996). The role of hypertension in the pathogenesis of heart failure: a clinical mechanistic overview. Arch Intern Med.
  125. (2006). The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation.
  126. Trends in heart failure incidence and survival in a community-based population.
  127. Trends in prevalence and outcome of heart failure with preserved ejection fraction.
  128. What works in chronic care management: the case of heart failure.